NAGE

+ Watchlist + Portfolio

Niagen Bioscience, Inc.

Physical products Consumer brandTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.79
52-Week Range: $2.61 – $7.95
Market Cap: $213.45M
P/E (TTM): 14.11
EPS (TTM): 0.19
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.57
PEG Ratio: —
Return on Equity: 21.80%
Return on Assets: 5.44%
Gross Margin: 64.24%
Operating Margin: 2.35%
Profit Margin: 12.39%
Current Ratio: 6.50
Debt/Equity: 0.03
Total Debt: $2.33M
Free Cash Flow: $1.64M
Revenue Growth: -4.30%
Earnings Growth: -75.00%
Enterprise Value: $148.25M

NAGE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$72.05M	$83.57M	$99.60M	$129.42M
Cost of Revenue	$29.25M	$32.79M	$38.01M	$46.23M
Gross Profit	$42.80M	$50.78M	$61.59M	$83.19M
Research & Development	$4.83M	$4.96M	$6.02M	$6.33M
Selling, General & Admin	$56.60M	$51.42M	$47.84M	$62.56M
Operating Expenses	$61.42M	$56.38M	$53.86M	$68.89M
Operating Income	-$18.63M	-$5.60M	$7.73M	$14.30M
EBITDA	-$16.74M	-$3.89M	$9.21M	$15.75M
Pretax Income	-$16.54M	-$4.94M	$8.86M	$18.19M
Income Tax	—	$0.00	$305.00K	$810.00K
Net Income	-$16.54M	-$4.94M	$8.55M	$17.38M
Diluted EPS	-0.24	-0.07	0.11	0.20
Diluted Shares	69.73M	74.98M	78.13M	85.44M

NAGE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.29M	$27.17M	$44.51M	$64.64M
Receivables	$8.48M	$5.23M	$7.77M	$9.74M
Inventory	$14.68M	$14.53M	$9.19M	$20.42M
Current Assets	$46.57M	$49.53M	$64.10M	$96.81M
Total Assets	$54.06M	$54.96M	$68.28M	$106.41M
Current Liabilities	$17.87M	$20.62M	$17.95M	$19.92M
Total Debt	$4.26M	$3.28M	$2.65M	$2.82M
Total Liabilities	$25.39M	$26.51M	$22.18M	$29.87M
Retained Earnings	-$185.49M	-$190.46M	-$181.91M	-$164.53M
Shareholders' Equity	$28.67M	$28.46M	$46.09M	$76.53M
Working Capital	$28.70M	$28.91M	$46.15M	$76.89M

NAGE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.10M	$7.12M	$12.11M	$13.50M
Capital Expenditure	-$334.00K	-$148.00K	-$163.00K	-$292.00K
Free Cash Flow	-$15.43M	$6.97M	$11.95M	$13.21M
Depreciation & Amortisation	$1.88M	$1.71M	$1.48M	$1.45M
Stock-Based Compensation	$5.74M	$4.75M	$3.66M	$6.07M
Investing Cash Flow	-$334.00K	-$143.00K	-$143.00K	-$292.00K
Financing Cash Flow	$7.65M	-$90.00K	$5.37M	$6.92M
Share Repurchases	—	—	$0.00	-$251.00K
Net Change in Cash	-$7.78M	$6.88M	$17.34M	$20.13M

NAGE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$30.48M	$31.12M	$33.99M	$33.84M	$31.47M	$29.79M
Cost of Revenue	$11.15M	$10.89M	$12.06M	$12.13M	$11.50M	$10.47M
Gross Profit	$19.33M	$20.23M	$21.93M	$21.70M	$19.98M	$19.31M
Research & Development	$1.26M	$1.57M	$1.79M	$1.71M	$1.48M	$1.51M
Selling, General & Admin	$13.30M	$15.47M	$15.90M	$17.89M	$16.92M	$17.10M
Operating Expenses	$14.56M	$17.04M	$17.69M	$19.60M	$18.40M	$18.61M
Operating Income	$4.77M	$3.19M	$4.24M	$2.10M	$1.58M	$700.00K
EBITDA	$5.14M	$3.54M	$4.59M	$2.47M	$2.04M	$1.17M
Pretax Income	$5.23M	$3.74M	$4.80M	$4.42M	$6.74M	$1.07M
Income Tax	$168.00K	$128.00K	$222.00K	$292.00K	$417.00K	$106.00K
Net Income	$5.06M	$3.61M	$4.58M	$4.13M	$6.32M	$963.00K
Diluted EPS	0.06	0.04	0.05	0.05	0.07	0.01
Diluted Shares	83.23M	86.24M	86.62M	84.44M	84.57M	82.50M

NAGE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$55.46M	$60.32M	$64.14M	$64.64M	$66.40M	$66.74M
Receivables	$7.05M	$9.66M	$8.51M	$9.74M	$13.07M	$8.58M
Inventory	$11.19M	$14.41M	$18.79M	$20.42M	$24.02M	$20.64M
Current Assets	$76.22M	$86.68M	$93.62M	$96.81M	$105.12M	$97.79M
Total Assets	$81.34M	$91.53M	$98.14M	$106.41M	$114.33M	$106.59M
Current Liabilities	$20.84M	$22.33M	$22.71M	$19.92M	$22.82M	$15.05M
Total Debt	$3.52M	$3.29M	$3.06M	$2.82M	$2.58M	$2.33M
Total Liabilities	$25.99M	$27.33M	$27.46M	$29.87M	$32.00M	$24.06M
Retained Earnings	-$176.85M	-$173.24M	-$168.66M	-$164.53M	-$158.21M	-$157.25M
Shareholders' Equity	$55.34M	$64.19M	$70.68M	$76.53M	$82.33M	$82.53M
Working Capital	$55.38M	$64.35M	$70.90M	$76.89M	$82.30M	$82.74M

NAGE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$7.88M	$1.25M	$3.69M	$679.00K	-$1.19M	$2.77M
Capital Expenditure	-$32.00K	-$135.00K	-$24.00K	-$101.00K	-$61.00K	-$89.00K
Free Cash Flow	$7.85M	$1.11M	$3.67M	$578.00K	-$1.25M	$2.68M
Depreciation & Amortisation	$368.00K	$355.00K	$359.00K	$368.00K	$464.00K	$470.00K
Stock-Based Compensation	$1.07M	$1.49M	$1.76M	$1.75M	$1.72M	$1.72M
Investing Cash Flow	-$32.00K	-$135.00K	-$24.00K	-$101.00K	$5.25M	-$92.00K
Financing Cash Flow	$3.10M	$3.74M	$148.00K	-$80.00K	-$2.29M	-$2.49M
Share Repurchases	$0.00	$0.00	—	—	-$2.35M	-$2.77M
Net Change in Cash	$10.96M	$4.86M	$3.82M	$498.00K	$1.76M	$191.00K

Market Snapshot

About

Niagen Bioscience, Inc. is a biotechnology company focused on NAD+ precursor supplements and longevity research. The company develops and markets nicotinamide riboside-based products targeting cellular health and aging.